International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Translational Research Award
Forecasted
The International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Translational Research Award supports researchers studying plasma cell disorders to improve myeloma care through clinical translation.
Browse similar grants
Funder: International Myeloma Society
Due Dates (Anticipated): January 2027 (research proposal)
Funding Amounts: $175,000–$250,000 USD; applicants may seek a second year
Summary: Supports investigator-initiated translational research on plasma cell disorders, with a focus on improving myeloma care.
Key Information: The principal investigator or a co-investigator must be an IMS member.
Description
The International Myeloma Society (IMS) and the Paula and Rodger Riney Foundation jointly run this award to support investigator-initiated translational research in plasma cell dyscrasias. Its goal is to improve prevention, early detection, diagnosis, and treatment of plasma cell disorders, with a particular focus on finding a cure for multiple myeloma. The program also seeks to encourage collaboration between institutions.
Projects may investigate molecular assays, imaging, drugs, biological agents, biomarkers, and other approaches relevant to myeloma treatment. Research can move discoveries toward clinical studies or use human biospecimens and findings from clinical studies to identify new targets and treatments. Projects must lead to clinical translation and pursue opportunities with the potential to change how myeloma is managed.
